DarioHealth (DRIO) Projected to Post Earnings on Monday

DarioHealth (NASDAQ:DRIO) is projected to announce its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($1.57) per share and revenue of $5.0480 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 8:30 AM ET.

DarioHealth Trading Down 2.9%

NASDAQ:DRIO opened at $9.70 on Friday. The stock has a market cap of $65.57 million, a price-to-earnings ratio of -0.87 and a beta of 1.08. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55. DarioHealth has a 1 year low of $5.93 and a 1 year high of $17.74. The business has a fifty day moving average of $11.27 and a 200-day moving average of $11.76.

Analyst Ratings Changes

Several equities analysts have commented on DRIO shares. Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a research note on Friday, November 14th. Wall Street Zen lowered shares of DarioHealth from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. TD Cowen reiterated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, DarioHealth has a consensus rating of “Hold” and an average price target of $38.00.

Institutional Trading of DarioHealth

Several institutional investors and hedge funds have recently added to or reduced their stakes in DRIO. Kestra Advisory Services LLC bought a new stake in DarioHealth during the fourth quarter worth approximately $35,000. Geode Capital Management LLC lifted its position in shares of DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after acquiring an additional 31,063 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in shares of DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after acquiring an additional 43,513 shares during the last quarter. 33.39% of the stock is owned by institutional investors and hedge funds.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.